Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Eisai Co., Ltd. (EII.F)

24.28

+0.45

+(1.89%)

At close: April 4 at 8:08:19 AM GMT+2

EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT06462404. Study sites are also planned for Canada.

PR Newswire 8 months ago

ESAIY

ESALF
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. L

PR Newswire 10 months ago

ESAIY

ESALF

BIIB

Performance Overview

Return	EII.F	Nikkei 225 (^N225)
YTD	-147.02%	-15.33%
1-Year	-75.17%	-15.07%
3-Year	+201.47%	+21.79%